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The calcitonin gene-related peptide (CGRP) family of G pro-
tein-coupled receptors (GPCRs) is formed through the associa-
tion of the calcitonin receptor-like receptor (CLR) and one of
three receptor activity-modifying proteins (RAMPs). Binding
of one of the three peptide ligands, CGRP, adrenomedullin
(AM), and intermedin/adrenomedullin 2 (AM2), is well
known to result in a Gs-mediated increase in cAMP.Here we
used modified yeast strains that couple receptor activation to
cell growth, via chimeric yeast/G subunits, and HEK-293
cells to characterize the effect of different RAMP and ligand
combinations on this pathway. We not only demonstrate
functional couplings to both Gs and Gq but also identify a
Gi component to CLR signaling in both yeast and HEK-293
cells, which is absent in HEK-293S cells. We show that the
CGRP family of receptors displays both ligand- and RAMP-
dependent signaling bias among the Gs, Gi, and Gq/11
pathways. The results are discussed in the context of RAMP
interactions probed through molecular modeling and molec-
ular dynamics simulations of the RAMP-GPCR-G protein
complexes. This study further highlights the importance of
RAMPs to CLR pharmacology and to bias in general, as well as
identifying the importance of choosing an appropriate model
system for the study of GPCR pharmacology.
Calcitonin gene-related peptide (CGRP),3 adrenomedullin
(AM), and adrenomedullin 2 (AM2, also known as intermedin)
are members of the calcitonin peptide family (1). This family
also includes calcitonin and amylin. CGRP, an extremely abun-
dant neuropeptide, is widely distributed throughout the sen-
sory nervous system. It is a very potent vasodilator released
during neurogenic inflammation and is particularly implicated
in the onset of migraine. It is also cardioprotective and is asso-
ciated with both pro- and anti-inflammatory actions (2, 3). AM
is produced by the vascular endothelium and has extensive
effects on the cardiovascular system including stimulation of
angiogenesis and the modulation of vascular tone (4–6).
AM2 affects the vascular system in a similar manner to AM
(7–9). Like CGRP, AM and AM2 are also cardioprotective,
and their administration results in decreased blood pressure
and increased speed of recovery from myocardial infarction
(10, 11).
CGRP, AM, and AM2 activate three receptors that share a
common class B G protein-coupled receptor (GPCR) subunit,
the calcitonin receptor-like receptor (CLR) (12). In each recep-
tor, CLR forms a heterodimer with receptor activity-modifying
protein (RAMP) 1, 2, or 3. The formation of this heterodimer is
obligatory for receptor function and efficient translocation of
both subunits to the cell surface (13). Heterodimerization with
RAMP1, RAMP2, or RAMP3 forms the CGRP, AM1, or AM2
receptor, respectively (13). The peptide ligands activate each
receptor with differing potencies (1, 12).
Activation of all threeCLR-based receptors byCGRP,AM, or
AM2 generates increased cAMP production through coupling
to the stimulatory G protein, Gs (1, 12, 14). However, CGRP,
AM, and AM2 can signal through other pathways (1, 15, 16).
Several studies have indicated that the CGRP family of recep-
tors can also couple to Gi/o subunits, because their cAMP
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responses can be significantly increased through treatment
with pertussis toxin (PTX), particularly in electrically excitable
cells (17–20). The AM/AM2 receptor cAMP signaling in HEK-
293 cells has also been shown to be PTX-sensitive (21). The
existing information on the stimulation of signaling by CGRP,
AM, or AM2 other than through the Gs-cAMP pathway has
been gained predominantly from physiological studies, and the
relative signaling bias of CGRP, AM, and AM2 at the three
CLR-based receptors, even for the cAMP pathway, remains to
be determined.
The study of signaling bias in vivo is complicated by cross-
talk from the wide range of signaling pathways present in cer-
tain cell lines or primary cell cultures. The Saccharomyces
cerevisiae growth system (22) provides a robust assay that
enables the examination of the coupling of a GPCR of choice to
single G protein subunits. This is achieved through replacing
the last five amino acids of the native yeast G protein with the
corresponding sequence from the human G protein of choice
(22, 23). This assay has recently been successfully employed to
characterize the signaling pathways underlying glucagon-like
peptide 1 (GLP-1) receptor response to GLP-1 and the many
receptor agonist mimetics available (24, 25). Miret et al. (26) in
2002 very elegantly described the functional expression of the
CLR with RAMP1 and RAMP2 in yeast. However, somewhat
surprisingly, given the more recent interest in signaling bias, a
further characterization of RAMP-CLR combinations in yeast
has not been performed.
In this study we have utilized S. cerevisiae to express either
RAMP1, -2, or -3 along with CLR to assess the coupling of the
three CGRP family receptors to different human G subunits
upon stimulation with CGRP, AM, or AM2. We demonstrate
that all members of the CGRP receptor family successfully cou-
ple to GPA1/Gs, GPA1/Gi, and GPA1/Gq yeast chimeras
and that the coupling preference of each receptor is dependent
upon the stimulating ligand. The results obtained from the
yeast systemwere verified in HEK-293mammalian cell lines by
the assessment of cAMP accumulation (which showed sensitiv-
ity to PTX) andmobilizations of intracellular calcium ((Ca2)i).
The data confirm that RAMPs alter the ability of each peptide
to couple to G proteins; they also indicate that the G proteins
influence the rank order of agonist potency at the different
receptors. For CGRP, AM, and AM2 this means that potent
activation of what would not generally be considered their
“normal” receptors can be observed when alternative down-
streampathways, such as stimulation of Gi ormobilizations of
(Ca2)i, are considered.
Considerable understanding of class B GPCR structure,
function, and dynamics has been gained (27), primarily through
molecular dynamics simulations (28–33). Consequently, to
gain insight into the possible mechanisms behind our experi-
mental results, we used molecular modeling and molecular
dynamics simulations of RAMP complexes with CLR and the
glucagon receptor (GCGR) to suggest a mechanism whereby
the C-terminal tail of the RAMPs may influence G protein bias
at the CLR. Finally we demonstrate that care is required when
selecting an appropriate mammalian cell line to use when
investigating G protein bias, as analysis of a HEK-293S cell line
failed to show Gi coupling for any of the RAMP-CLR com-
plexes, thus highlighting the fact that agonist bias can be
directly influenced by the cellular background.
Results
Gs Coupling of CLR-based Receptors—We co-expressed
CLR under the control of the strong PGK promoter with
RAMP1, RAMP2, or RAMP3 independently in a yeast strain
containing a chimeric G subunit in which the C-terminal five
amino acids of GPA1 had been replaced with those of mamma-
lian Gs, in order to study the coupling of the resultant recep-
tors to a system expressing just a single G protein. Concen-
tration-response curves were constructed for growth of
S. cerevisiae for each RAMP-CLR combination (i.e. the CGRP,
AM1, and AM2 receptors) using the agonists CGRP, AM, and
AM2. When CLR was co-expressed with RAMP1, all three
ligands appeared to generate an equivalent level of response but
with differing potencies (Fig. 1A and Table 1). This generated a
rank order of potency for the three ligands of CGRP  AM 
AM2. Application of the operational model of pharmacological
agonism (34) indicates that all three ligands exhibit similar effi-
cacies (log ) in yeast when CLR and RAMP1 are co-expressed
(Fig. 1D and Table 1). RAMP2 co-expression with CLR gener-
ated a functional receptor (Fig. 1B) with rank ligand potencies
of AM  AM2  CGRP. AM2 appeared to behave as a partial
agonist with a reduced log  at the RAMP2-CLR heterodimer
when compared with the other peptide agonists (Table 1). AM
had a significantly higher efficacy (p 0.05) than that displayed
by CGRP. Expression of RAMP3 with CLR in S. cerevisiae gen-
erated a functional receptor where all three ligands activated
GPA1/Gs-coupled signaling with similar potencies and effica-
cies (Fig. 1C).
We sought to confirm the pharmacology observed in the
S. cerevisiae growth assay of the RAMP-CLR complexes in
mammalian cell lines. For this we used HEK-293 cells that do
not functionally express any RAMPs (25). Co-transfection of
CLR and RAMP1 generated a rank order of ligand potency of
CGRP AM AM2. The rank order of ligand potency with
co-transfection of CLR and RAMP2was AMCGRPAM2
and for CLR and RAMP3 was AM2 AM CGRP (Fig. 2 and
Table 2). It is worth noting that, in our HEK-293 cells, only AM
acted as a full agonist against the CLR when in complex with
either RAMP2 or RAMP3. Overall the mammalian and yeast
data showed similar results, with themost potent ligand at each
receptor remaining the same in each case.
Gi Coupling of CLR-based Receptors—To address the possi-
bility that the CGRP family of receptors may couple not only to
Gs but also to other subunits, we returned to the S. cerevisiae
growth assay. In this case the yeast strain used contained a chi-
meric GPA1/G subunit including the last five residues of
mammalian Gi. We once again constructed concentration-
response curves for yeast growth to the three agonists, CGRP,
AM, andAM2. The co-expression of CLR and RAMP1 resulted
in similar potencies for CGRP, AM, and AM2 (Table 1); how-
ever, AM and AM2 displayed significantly increased efficacy
relative to CGRP for the activation of GPA1/Gi (Table 1
and Fig. 3,A andD). In contrast, when RAMP2 and CLRwere
co-transformed into the GPA1/Gi yeast strain, the rank
order of ligand potency for GPA1/Gi yeast-based growth
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was CGRPAMAM2 (Table 1 and Fig. 3B). AM2 showed
a significantly decreased efficacy compared with the other
peptides (Table 1 and Fig. 3D). As with the RAMP1-CLR
heterodimer, the combination of CLR and RAMP3 expressed
in the GPA1/Gi strain resulted in similar potencies for
CGRP, AM, and AM2 (Table 1 and Fig. 3C). However, AM2
displayed a significantly reduced efficacy when compared
with AM (Table 1 and Fig. 3D).
FIGURE1.Functional expressionofCLRco-transformedwithall threeRAMPs inyeast cells.Dose-response curves toCGRP,AM, andAM2were constructed
in yeast strains containing the GPA1/Gs chimera and expressing CLRwith RAMP1 (n 6) (A), RAMP2 (n 7) (B), and RAMP3 (n 8) (C). Reporter gene activity
was determined following 20 h of stimulationwith each ligand. Data are expressed as a percentage of themaximum response observed in yeast strainMMY11
(lacking GPA1) and aremeans S.E. of n individual data sets.D, bar chart showing the efficacy of each ligand for each RAMP-CLR combination as determined
via application of the operational model of receptor agonism (see Ref. 34 and Table 1). Data were determined as statistically different from the cognate ligand
for each receptor (*, p 0.05; **, p 0.01; ***, p 0.001) using a one-way ANOVA with Bonferroni’s post-test.
TABLE 1
Summary of pharmacological parameters for various ligands upon expression of the CLRwith each RAMP in yeast strains containingGPA1/Gs,
GPA1/Gi, or the GPA1/Gq chimera
Data are themean S.E. of n individual data sets. Statistical significance compared with the cognate ligand (*, p 0.05; **, p 0.01; ***, p 0.001; ****, p 0.0001) for each
receptor heterodimer (CGRP for RAMP1 CLR and AM for CLR with either RAMP2 or RAMP3) was determined by one-way ANOVA with Dunnett’s post-test.
RAMP1-CLR RAMP2-CLR RAMP3-CLR
CGRP AM AM2 CGRP AM AM2 CGRP AM AM2
GPA1/Gs
pEC50a 9.35 0.2* 8.80 0.4*** 7.22 0.3*** 7.60 0.3* 8.82 0.3* 8.05 0.3* 8.24 0.2 8.15 0.4 8.85 0.3
Emaxb 27.10 1.6* 20.39 2.8*** 20.65 1.1*** 30.34 4.1 37.46 3.5 19.90 2.5*** 30.17 2.7 25.51 3.6 22.80 2.3
pKac 9.22 0.2* 8.81 0.3*** 7.31 0.3*** 7.70 0.3* 8.77 0.3 8.10 0.3 8.30 0.3 8.10 0.3 8.61 0.4
log d 0.43 0.04 0.59 0.07* 0.61 0.08 0.38 0.08* 0.23 0.06 0.61 0.06** 0.42 0.08 0.51 0.08 0.57 0.08
n 6 6 6 7 7 7 8 8 8
GPA1/Gi
pEC50a 8.26 0.5 8.38 0.3 * 8.57 0.2** 8.89 0.2** 7.91 0.2** 8.42 0.5** 8.52 0.2 7.89 0.8 8.49 0.2
Emaxb 19.80 3.0* 34.20 3.7*** 41.5 3.3**** 24.43 1.7* 24.49 2.0* 15.71 2.5* 22.60 1.8* 26.71 1.8* 15.71 2.1*
pKac 8.40 0.5 8.20 0.3** 8.24 0.2 8.64 0.2 7.75 0.2 8.30 0.5 8.37 0.2 8.00 0.2 8.30 0.3
log d 0.70 0.1** 0.33 0.07** 0.18 0.1*** 0.50 0.04** 0.51 0.05* 0.89 0.1** 0.56 0.06* 0.50 0.05* 0.78 0.07*
n 6 6 6 6 6 6 7 7 7
GPA1/Gq
pEC50a 7.53 0.1 7.26 0.2 7.99 0.2 7.14 0.2 7.93 0.2 9.22 0.4* 6.19 0.5* 7.83 0.2 6.76 0.25
Emaxb 26.50 1.2 14.08 1.2**** 16.73 1.1**** 27.74 2.3 29.03 2.6 11.33 1.3**** 20.7 4.2 25.56 2.0 32.11 3.7
pKac 27.40 0.1 7.19 0.2 7.91 0.03 7.01 0.2 7.78 0.2 9.16 0.4* 6.10 0.6* 7.71 0.2 6.60 0.3
log d 0.46 0.03 0.79 0.04*** 0.70 0.04*** 0.42 0.05 0.39 0.05 0.88 0.08*** 0.63 0.2 0.48 0.05 0.34 0.1
n 7 7 7 6 6 6 6 6 6
a The negative logarithm of the agonist concentration required to produce a half-maximal response.
b The maximal response to the ligand expressed as a percentage of that obtained from a yeast strain (MMY11) lacking GPA1.
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34).
d Log  is the coupling efficacy parameter of each ligand.
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In mammalian cells the Gs and Gi subunits act in opposi-
tion to regulate cAMP production. Therefore if a receptor can
couple to both subunits in mammalian cells, the cAMP
response measured is the result of a combination of the contri-
bution from both pathways. Treatment of cells with PTX has
been shown to uncouple receptors from the Gi subunit and
therefore remove any inhibition of cAMP production. We
sought to confirm the apparent Gs-Gi coupling bias exhib-
ited by the different RAMP-CLR combinations in the yeast
reporter strains by measuring cAMP production from tran-
siently transfected mammalian cells following PTX treatment.
Pretreatment of HEK-293 cells co-expressing RAMP1 with
the CLR resulted in little overall increase in CGRP-mediated
cAMP production (Fig. 4A). However, a significant elevation in
Emax was observed in the same PTX-treated, RAMP1-CLR-ex-
pressing cells when challenged with either AM or AM2 (Fig. 4
andTable 3), suggesting that aGi component for both of these
ligands had been removed (Table 3). HEK-293 cells expressing
CLRwith either RAMP2 (Fig. 4B) or RAMP3 (Fig. 4C) displayed
PTX-induced increases inEmax for cAMPaccumulation follow-
ing stimulation with both CGRP and AM2 (Table 3). However,
for both combinations, the AM response appeared to be unaf-
fected by PTX treatment, suggesting that little Gi coupling
was present. Indeed, it is worth noting, that the cognate ligand
for each receptor (CGRP for RAMP1-CLR and AM for
RAMP2-CLR or RAMP3-CLR) did not appear to display an
FIGURE 2. Expression of CLR in combination with each RAMP generates functional Gs-coupled receptors in HEK-293 cells. cAMP accumulation was
determined inHEK-293 cells transiently transfectedwith theCLRandRAMP1 (n11) (A), RAMP2 (n8) (B), andRAMP3 (n9) (C) following30-min stimulation
with CGRP, AM, and AM2. Data are expressed as percentage of cAMP production, determined using 100 M forskolin stimulation, and are means S.E. of n
individual data sets. D, bar chart showing the efficacy of each ligand for each RAMP-CLR combination as determined via application of the operational model
of receptor agonism (34). Data were determined as statistically different from the cognate ligand for each receptor (*, p 0.05; **, p 0.01) using one-way
ANOVA with Bonferroni’s post-test.
TABLE 2
Potency (pEC50), affinity (pKa) and coupling efficacy (log ) values for cAMPproduction at the CLR co-expressedwith each RAMPand stimulated
with various agonists measured in HEK-293 cells
Data are the mean  S.E. of n individual data sets. Statistical significance compared with the cognate ligand (*, p  0.05; **, p  0.01; ***, p  0.001) for each receptor
heterodimer (CGRP for RAMP1-CLR and AM for CLR with either RAMP2 or RAMP3) was determined by one-way ANOVA with Dunnett’s post-test.
RAMP1-CLR RAMP2-CLR RAMP3-CLR
CGRP AM AM2 CGRP AM AM2 CGRP AM AM2
pEC50a 9.81 0.20 7.92 0.19** 7.93 0.24** 8.97 0.24*** 10.35 0.13 7.48 0.23*** 7.75 0.3** 8.86 0.14 9.14 0.22**
Emaxb 45.0 2.2 45.2 3.7 43.6 4.2** 37.2 2.4*** 55.0 1.7 34.1 4.0** 22.3 2.1** 32.1 1.6 21.9 1.7**
pKac 9.60 0.18 7.64 0.28** 7.76 0.20** 8.71 0.2** 9.95 0.23 7.16 0.24** 7.64 0.26** 8.50 0.19 9.00 0.18**
log d 0.08 0.04 0.08 0.09** 0.11 0.06** 0.23 0.05*** 0.09 0.05 0.29 0.07** 0.54 0.06** 0.33 0.04 0.56 0.04**
n 11 11 11 8 8 8 9 9 9
a The negative logarithm of the agonist concentration required to produce a half-maximal response.
b The maximal response to the ligand expressed as a percentage of the maximal cAMP production as determined using 100 M forskolin stimulation.
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34).
d Log  is the coupling efficacy parameter of each ligand.
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increased Emax upon PTX treatment, suggesting limited Gi
components in these cases. Importantly, PTX treatment of
untransfected HEK-293 cells did not result in a change in the
overall levels of cAMPaccumulation as determinedby forskolin
stimulation (untreated, 16.57  2.5 pmol cell1; treated,
16.45  2.4 pmol cell1), thereby confirming that the effects
observed were specific to the RAMP-CLR combinations. Thus,
there is abundant evidence that receptor and ligands can acti-
vate Gi in a mammalian cell, albeit in a complex pattern.
Cell Line Variability in G Protein Expression—The HEK-293
human cell lineage has undergone a number of modifications
(35). One such lineage, HEK-293S, was adapted for growth in
suspension (36). Interestingly, HEK-293S lines have also been
reported to lack expression of RAMPs and therefore provide an
alternative background for investigating the modulation of
GPCR signal transduction (37, 38). Given that previous reports
suggest that some of the effects observed with RAMPs are cell
type-dependent (37, 39), we utilizedHEK-293S cells as an alter-
native cell line. Surprisingly, and in contrast to what was
observed for HEK-293 cells, HEK-293S cells pretreated with
PTX and co-expressing RAMP1, RAMP2, or RAMP3with CLR
failed to demonstrate any significant change in either potency
or Emax when challenged with CGRP, AM, or AM2 (Fig. 5 and
Table 4; compare with Fig. 4). These results suggest that in
HEK-293S cells, the RAMP-CLR combinations display little
Gi-mediated responses. This led us to speculate about the
respective G protein content for the two cell lines. Using semi-
quantitative RT-PCR we assessed the expression of 12 G sub-
units (Fig. 6, A and B) in both mammalian cell lines. In the
HEK-293 cells we were able to detect the expression of ten G
subunits, with a profile similar to that documented previously
for these cells (40). Transcriptswere not detectable for theG14
or G15 subunits. Interestingly, in comparison with the HEK-
293 cells, the HEK-293S cells displayed significantly lower
expression of two Gi subunits (relative to GAPDH) but
broadly similar levels of all others G subunits. Furthermore,
there was a much better correlation between the pEC50 values
for the ligands on HEK-293 and HEK-293S cells when the for-
mer had been pretreated with PTX, to remove the Gi compo-
nent, suggesting that the differences in Gi expression between
the two cell lines have functional significance (Fig. 6C, r 0.80
(95% confidence interval, 0.27–0.96)with PTX versus 0.52 (95%
confidence interval, 0.22 to 0.89) without PTX; p  0.05).
Importantly, these data demonstrate the need for cautionwhen
choosing cells for assessing G protein-mediated signaling
responses.
Gq/11 Coupling of CLR-based Receptors—To provide a com-
plete investigation of the G protein coupling of the RAMP-CLR
complexes, we extended our study to include the remaining
nine GPA1/G yeast chimera-expressing strains. Coupling
with the RAMP-CLR heterodimers was observed only in one
additional strain that representing Gq (strain MMY89). Con-
centration-response curves were generated (Fig. 7, A–C, and
Table 1), demonstrating that at RAMP1-CLR all three ligands
displayed similar potencies, with CGRP being the most effica-
cious (log , Table 1) as expected for the cognate ligand at this
FIGURE3.Co-transformationofCLRwithall threeRAMPs inyeast cells generates receptors that couple functionally to theGi chimera.Dose-response
curves to CGRP, AM, and AM2 were constructed in yeast strains containing the GPA1/Gi chimera and expressing CLR with RAMP1 (n 6) (A), RAMP2 (n 6)
(B), andRAMP3 (n7) (C). Reporter gene activitywasdetermined following20hof stimulation. All data are expressed aspercentageof themaximumresponse
observed in yeast strain MMY11 (lacking GPA1) and are means  S.E. of n individual data sets. D, bar chart showing the efficacy of each ligand for each
RAMP-CLR combination asdeterminedvia applicationof theoperationalmodel of receptor agonism (Ref. 34 andTable 1). Dataweredeterminedas statistically
different from the cognate ligand for each receptor (*,p0.05; **,p0.01; ***,p0.001; ****,p0.0001) usingaone-wayANOVAwithBonferroni’s post-test.
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receptor. AM2 is the most potent ligand when activating the
RAMP2-CLR complex, having a reduced Emax and log  relative
to CGRP andAM (Table 1).With RAMP3-CLR, a rank order of
ligand potency of AM  AM2  CGRP was observed (Fig. 7C
and Table 1), with all three ligands displaying broadly similar
efficacies (Table 1).
Ligand-engendered G Protein Bias—To provide a means by
which to determine the relative bias each agonist displays at
each RAMP-CLR complex for the three different chimeric G
proteins (in yeast), we calculated the bias factor (expressed
as(/Ka)) (41). For theRAMP1-CLRheterodimer, the values
were calculated relative to CGRP, whereas when CLR was
expressed with RAMP2 or RAMP3 the reference ligand was
AM. In all cases the reference pathway used was GPA1/Gs
(Fig. 7E). The bias plots demonstrated that at the RAMP1-CLR
complex, AM2 showed a much greater bias toward signaling
via GPA1/Gi and GPA1/Gq relative to CGRP, whereas AM
showed a bias profile approximately equal to CGRP. With
RAMP2-CLR, however, CGRP showed a much greater bias
toward GPA1/Gi signaling over GPA1/Gs and GPA1/Gq,
whereas AM2wasmore biased toward GPA1/Gq. In the pres-
ence of RAMP3 all three ligands were equally biased toward
GPA1/Gs and GPA1/Gi, but CGRP and AMwere less biased
toward GPA1/Gq signaling relative to AM2.
Activation of RAMP-CLRComplexes Leads toMobilization of
Intracellular Ca2 inMammalian Cells—To confirm our find-
ings from S. cerevisiae, we again utilized HEK-293 cells tran-
siently expressing theCLR in conjunctionwith each RAMPand
measured the release of (Ca2)i upon stimulation with CGRP,
AM, and AM2. Although all three ligands resulted in calcium
FIGURE 4. CLR in combination with each RAMP generates receptors that display PTX-sensitive effects in response to ligand stimulation. cAMP accu-
mulationwas determined in the presence (treated) and absence (untreated) of PTX fromHEK-293 cells transiently transfectedwith CLR and RAMP1 (n 6) (A),
RAMP2 (n 5) (B), and RAMP3 (n 5) (C). Cells were stimulated for 30 min with CGRP, AM, and AM2. Data are expressed as percentage of the maximal cAMP
production as determined using 100 M forskolin stimulation in the presence of PTX and are means S.E. of n individual data sets.
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mobilization at each RAMP-CLR complex (Fig. 8 and Table 5),
these results differed slightly from that observed in S. cerevisiae.
At both RAMP1 and RAMP2-CLR a rank order of ligand
potency of CGRP AM AM2 was seen, whereas CGRP was
the most efficacious ligand (Table 5). With RAMP3-CLR, both
AM and AM2 were equipotent, with CGRP being the least
potent agonist. Treatment with PTX was seen to have no effect
upon the levels of calcium released in response to the three
ligands, at any RAMP-CLR complex.
To confirm our yeast findings that the CLR can couple to
Gq and thereby promote (Ca2)i mobilization in mammalian
cells, we utilized the known selective Gq/11 inhibitor
YM-254890 (42). Pretreatment with YM-254890 for 30 min
prior to stimulationwithAMandAM2was sufficient to abolish
all (Ca2)imobilization at all RAMP-CLR complexes. Further-
more, the response toCGRP at all three RAMP-CLR complexes
was also considerably attenuated with (Ca2)i release, being
detected only when cells were stimulated with CGRP in the
micromolar range. Similar data were obtained using HEK-293S
cells (Table 5), suggesting that despite differences in Gi con-
tent, the release of (Ca2)i was consistent between the two cell
types. These finding suggest that all three ligands are able to
initiate calcium mobilization at all three RAMP-CLR com-
plexes in a Gq-dependent manner in both mammalian cell
lines.
Pathway Bias at the RAMP-CLR Complexes—Through cal-
culating the change in the ratio of log(/Ka) between cAMP
accumulation and the release of (Ca2)i, it is possible to deter-
mine the extent of signaling bias for a ligand (Fig. 9A). In HEK-
293 cells all ligands showed cAMP bias over (Ca2)i, except for
AM2 and CGRP at RAMP2-CLR and RAMP3-CLR, respec-
tively. In contrast, in HEK-293S cells all ligands showed clear
bias toward cAMP at each RAMP-CLR complex. Interestingly,
treatment of HEK-293 cells with PTX generated bias profiles
similar to that observed for HEK-293S cells (Fig. 9).
Further analysis of these bias factors relative to the cognate
ligand at eachRAMP-CLR complex (Fig. 9B) indicates that only
AM2 displays bias toward cAMP at the RAMP1- and RAMP3-
CLR complexes, whereas all other ligands display a preference
tomobilize (Ca2)i. Again, this is slightly different than the bias
profile forHEK-293S cells. At theRAMP1-CLR complex, AM is
biased toward (Ca2)i, and AM2 is cAMP-biased. For RAMP2-
CLR, CGRP is biased toward (Ca2)i mobilization, whereas
AM2 is neutral. At RAMP3-CLR all ligands are neutral and
display no bias. As noted above, the inhibition of any signaling
input fromGi in HEK-293 cells via PTX treatment generates a
relative bias profile comparable with that seen in HEK-293S
cells. Thus, we show that not only do RAMPs play a significant
role inmodulating signaling bias but also that cellularG protein
content can drastically modulate any perceived bias.
Molecular Modeling of CLR and GCGR in Complex with
RAMPs—Our experimental data suggest that RAMPsmay per-
form a critical role in modulating G protein coupling and bias.
However, we do not as yet have any insight into themechanism
by which this may be achieved. To at least partially address this
issue, we turned to the use of molecular modeling. We gener-
ated models of GCGR in complex with RAMP2 and CLR in
complex with RAMP1. We used the GCGR system because it
provides a reference system. The interaction between the pep-
tide and the ligand is particularly well defined in the homo-
logous GLP-1R system through reciprocal mutagenesis and
photoaffinity labeling (28, 29); also we have shown that the
interaction between GCGR and RAMP2 affects G protein bias
(25). Models taken from the last step in the 500-ns trajectory
show that in both cases, the C-terminal region of the RAMP
resides in the vicinity of helix 8 (H8), the intracellular ends of
TM6 andTM7, and theC-terminal region ofGs (Fig. 10,A and
B). There are differences in the orientation of the extracellular
domain and the precise location of the RAMP transmembrane
(TM) helix due to the dynamic nature of the systems, the longer
“stalk” (the region between the extracellular domain and TM1)
in GCGR, and the sequence differences between the receptors
and between RAMP1 and RAMP2. There are no direct interac-
tions between the RAMPs and the peptide ligands.
Analyses of the MD trajectories show that for GCGR and
CLR, theC-terminal region of the RAMPapproaches theC-ter-
TABLE 3
Potency (pEC50), affinity (pKa), and coupling efficacy (log ) values for cAMP production at the CLR co-expressed with each RAMP, stimulated
with various agonists measured in HEK-293 cells in the presence and absence of pertussis toxin
Data are the mean S.E. of n individual data sets. Statistical difference between PTX-treated and untreated cells was determined using Student’s t test (*, p 0.05; **, p
0.01; ***, p 0.001; ****, p 0.0001).
Untreated Treated
pEC50a Emaxb pKac log d n pEC50a Emaxb pKac log d n
RAMP1
CGRP 9.66 0.2 47.07 2.2 9.43 0.2 0.11 0.04 9 9.65 0.2 44.95 2.2 9.33 0.3 0.11 0.07 6
AM 7.93 0.2 48.06 2.5 7.67 0.2 0.09 0.05 9 8.14 0.07 72.17 1.7*** 7.66 0.2  0.36 0.1** 6
AM2 7.93 0.2 46.10 4.1 7.70 0.2 0.11 0.07 9 9.15 0.1*0 72.15 2.4*** 8.56 0.3  0.40 0.1** 6
RAMP2
CGRP 19.00 0.2 36.97 2.4 18.82 0.2 0.27 0.05 9 18.25 0.4 56.27 1.4*** 7.92 0.2* 0 0.1 0.06** 6
AM 10.35 0.1 56.33 1.6 10.00 0.1 0.07 0.02 9 10.16 0.07 56.07 1.1 9.83 0.2 0.07 0.02 6
AM2 17.46 0.2 36.61 3.5 17.24 0.2 0.29 0.07 9 19.13 0.1** 56.05 2.2*** 8.84 0.2** 00.1 0.06* 6
RAMP3
CGRP 7.75 0.3 22.38 2.6 7.64 0.3 0.54 0.07 8 8.90 0.1* 32.61 1.5* 8.74 0.2* 0.29 0.06 7
AM 8.98 0.2 32.00 1.5 8.83 0.1 0.33 0.03 8 9.10 0.2 35.95 2.2 8.94 0.2 0.34 0.05 7
AM2 9.10 0.2 21.92 1.7 9.08 0.2 0.51 0.06 8 8.74 0.2 44.35 2.7**** 8.43 0.1* 0.07 0.07*** 7
a The negative logarithm of the agonist concentration required to produce a half-maximal response.
b The maximal response to the ligand expressed as a percentage of the maximal cAMP production as determined using 100 M forskolin stimulation in the presence of per-
tussis toxin treatment.
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34).
d Log  is the coupling efficacy parameter of each ligand.
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minal peptide of the G protein within the first 100 ns (Fig. 10C).
For GCGR the primary interaction is with the G protein, but
there are also interactions with H8. For CLR the first part of the
tail interacts with the G protein, whereas the tip of the tail
interacts with H8; in both CLR and GCGR there are also inter-
actions with the intracellular end of TM6. The interactions are
driven by a combination of steric, hydrophobic, and electro-
static factors. Movies of both simulations are provided as sup-
porting information (supplemental Movies 1 (RAMP2-GCGR-
Gs) and 2 (RAMP1-CLR-Gs)).
The extracellular end of TM7 of GCGRmoves inward under
the influence of RAMP2. Analysis of the distances between the
extracellular end of TM2 (C of residue Lys-205), TM7 (C of
residue Gly-375), the RAMP2 linker (C of residue Val-145),
and the peptide (C of residue Tyr-13) shows that the RAMP
TM, TM7, and the peptide move as a collective unit toward
TM2 (Fig. 11), indicating a mechanism whereby the peptide
ligand can influence the RAMP and vice versa even in the
absence of a direct interaction.
Discussion
The pharmacology of the CGRP family of receptors is rela-
tively well characterized with respect to Gs coupling and the
resultant accumulation of cAMP (1, 12). Gq and Gi coupling
to these receptors, however, is less well characterized. Here we
report the extension of the use of the S. cerevisiae system to
investigate signaling bias in the CGRP family of receptors.
These receptors are obligate heterodimers of the GPCR,
namely CLR with one of three RAMPs. This dimerization adds
an increased level of complexity to the system.We find that the
FIGURE 5. RAMP-CLR responses appear PTX-insensitive when assayed using HEK-293S cells. cAMP accumulation was determined in the presence
(treated) and absence (untreated) of PTX fromHEK-293S cells transiently transfectedwith CLR and RAMP1 (n 5) (A), RAMP2 (n 5) (B), and RAMP3 (n 5) (C).
Cells were stimulated for 30 min with CGRP, , and AM2. Data are expressed as percentage of the maximal cAMP production as determined using 100 M
forskolin stimulation in the presence of PTX and are means S.E. of n individual data sets.
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RAMPs influence the G protein coupling in a ligand- and
receptor-dependent manner, in some cases radically changing
ligand selectivity.
WhenGPA1/Gi coupling in the yeast systemwas compared
with coupling toGPA1/Gs, markedly different responses were
observed for each ligand. Most significantly, at all three recep-
tors, the rank order of potency of the ligands was altered, either
being reversed or with differences abolished. Efficacy calcula-
tions for each ligand in the presence of GPA1/Gi also revealed
G protein-directed changes in the activity of each ligand. AM2
displayed a much greater efficacy at the RAMP1-CLR het-
erodimer than AM, and surprisingly CGRP efficacy was greatly
reduced. These data indicate that the ligands display a degree of
G protein bias at each receptor; this was further supported
through the construction of bias plots through calculation of
(/Ka). The data contrast with the established potency pro-
files for Gs-coupled receptors observed in mammalian cells
and also yeast. Although Gs is recognized as the main signal-
ing pathway activated by CLR-based receptors (15), the data
illustrate that if Gi or Gq activation occurs, the conventional
agonist potency ratiosmay lead to erroneous conclusions about
the nature of the receptor. Caution should at least be taken
when referring to these receptors, because it is clear that CGRP
will preferentially activate the Gs-coupled CGRP receptor
(RAMP1-CLR), but this is not the situationwhen the receptor is
coupled to other G proteins. Indeed, this trend is observed for
all receptors in this family, with AM being the preferential
ligand for both the AM1 (RAMP2-CLR) and AM2 (RAMP3-
CLR) receptors coupled to Gs but not when Gi coupled. To
avoid confusion we have, for the most part, described these
receptors as RAMP1/2/3-CLR in this study.A further point that
arises from these observations is that the reversals in potency
ratios that we observed suggest that differences in the ability of
the peptides to penetrate the yeast cell wall are not a contribut-
ing factor to our observations.
Our data also shed new light on the comparative efficacies of
CGRP, AM, and AM2 at the three receptors for Gs coupling.
Typically, they have been reported to show similar maximal
responses, although there are issues with incomplete concen-
tration-response curves (1). However, there is evidence for par-
TABLE 4
Potency (pEC50) andmaximal response (Emax) for cAMP production at
the CLR co-expressed with each RAMP stimulated with various ago-
nistsmeasured inHEK-293S cells in thepresence or absence of pertus-
sis toxin
Data are themean S.E. ofn individual data sets.No statistical differencewas found
between untreated and PTX-treated HEK-293S cells using Student’s t test.
Untreated Treated
pEC50a Emaxb n pEC50a Emaxb n
RAMP1
CGRP 9.88 0.1 59.98 1.1 5 9.87 0.1 72.92 2.3 5
AM 8.13 0.1 60.00 3.1 5 8.03 0.1 61.26 2.6 5
AM2 8.74 0.1 68.94 1.2 5 8.78 0.1 68.30 1.6 5
RAMP2
CGRP 8.00 0.1 32.56 1.0 5 7.88 0.1 39.32 1.7 5
AM 9.39 0.1 30.34 0.8 5 9.38 0.1 33.28 1.2 5
AM2 8.57 0.1 40.30 1.5 5 18.58 0.16 30.52 2.0 5
RAMP3
CGRP 8.42 0.1 40.84 0.6 5 8.38 0.1 39.84 1.0 5
AM 9.63 0.1 39.09 1.2 5 9.49 0.2 42.26 1.6 5
AM2 8.01 0.1 33.75 1.5 5 7.79 0.2 28.21 2.4 5
a The negative logarithm of the agonist concentration required to produce a half-
maximal response.
b The maximal response to the ligand expressed as a percentage of the maximal
cAMP production as determined using 100 M forskolin stimulation in the pres-
ence of PTX treatment.
FIGURE 6. Reduced Gi expression in HEK-293S cell lines leads to PTX
insensitivity. A, expression profiles of G genes were assessed in HEK-293
andHEK-293S cells. RNAwas extracted fromcells and treatedwithDNase 1 to
remove genomic DNA contamination. G gene expression was examined by
RT-PCRusinggene-specific primers. *, indicates a lack of detectable transcript
for Gi2. The band shown is a nonspecific product as confirmed by DNA
sequencing. B, semiquantitative expression (relative to GAPDH) for the G
genes from A (n 4). Statistical difference between HEK-293 and HEK-293S
cells was determined using Student’s t test: *, p  0.05; **, p  0.01. C, the
correlation of log agonist potencies S.E. for CGRP, AM, and AM2 at RAMP-
CLR combinations expressed in HEK-293S (Table 4) cells and HEK-293 cells
eitherwith (red symbol) orwithout (blue symbol) pretreatmentwithPTX (Table
3) was analyzed by a scatter plot, and Pearson’s correlation coefficients (r)
were calculated. A significant correlation was observed only between HEK-
293S cells and HEK-293 cells pretreated with PTX.
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tial agonism of AM2 in CHO cells when RAMP2 is co-ex-
pressed with CLR (43). By its nature, the measurement of
efficacy is very sensitive to the cell or tissue being studied aswell
as the experimental protocol. In this study, the use of the yeast
assay enabled us to calculate the efficacy and potency values for
each ligand-receptor combination for specific G protein sub-
FIGURE 7. Functional coupling of CLR co-transformed with all three RAMPs to the Gq chimera. Dose-response curves to CGRP, AM, and AM2 were
constructed in yeast strains containing the GPA1/Gq chimera and expressing CLRwith RAMP1 (n 7) (A), RAMP2 (n 6) (B), and RAMP3 (n 7) (C). Reporter
gene activity was determined following 24-h stimulation. All data are expressed as percentage of themaximum response observed in yeast strainMMY11 and
aremeans S.E. of n individual data sets.D, Bar chart showing the efficacy of each ligand for each RAMP-CLR combination at the Gq chimera determined via
application of the operationalmodel of receptor agonism (Ref. 34 and Table 1). Datawere determined as statistically different from the cognate ligand for each
receptor (***, p 0.001; ****, p 0.0001) using one-way ANOVA with Bonferroni’s post-test. E, signaling bias plots were calculated as (/Ka) values on a
logarithmic scale for each ligand and for each chimeraGprotein for the three individual RAMP-CLR complexes. Determination of values requires normalization
to a reference ligand (CGRP for RAMP1-CLR and AM for CLR with RAMP2 or RAMP3) and a reference pathway (in all cases, GPA1/Gs).
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units without the complication of pathway cross-talk. Our data
revealed that all ligands have similar efficacies in cells express-
ing the RAMP1-CLR combination coupled to GPA1/Gs. In
contrast, AM has a significantly increased efficacy at the
RAMP2-CLR heterodimer.
The relative potencies of the three peptides at the CGRP,
AM1, and AM2 receptors that we observed in our current stud-
ies for Gs coupling largely agree with previous observations (1
for review, 7–9, 43, and 44) (Table 2 and Fig. 12). Importantly
when each receptor was expressed in S. cerevisiae strains, ena-
bling us to measure the activation of GPA1/Gs, the rank
potency order for the peptides fit the pattern observed inmam-
malian cells (Table 1 and Fig. 9), with the exception of CGRP,
which displayed an unexpectedly high potency at the RAMP3-
CLR heterodimer. These data indicate that, as with the GLP-1
and glucagon receptors, the yeast system is a valid model for
studying G protein coupling to class BGPCRs. The comparable
pharmacology of the three receptors demonstrates the value of
the yeast system for assessment of the effect of complex forma-
tion by GPCRs and could be applied not only to dimerization of
these receptors with RAMPs but also othermodifying or down-
stream signaling proteins.
An important consideration is whether the Gi/Gq cou-
pling observed in yeast has any relevance to mammalian cell
systems. The yeast strains express only chimeric G proteins
(containing the C-terminal five amino acids of the human G
protein), which are reported to be less specific when compared
with equivalent G proteins expressed in mammalian cells (22).
To establish the extent of Gi coupling in HEK-293 cells, we
investigated cAMPproduction before and after PTX treatment;
the greater the enhancement of cAMP production following
toxin addition, the greater the extent of Gi coupling that the
toxin inactivates. When compared with the coupling seen in
yeast to GPA1/Gi, although the correlation is not exact, there
FIGURE 8.CLR in combinationwith eachRAMPgenerates receptors thatmobilize (Ca2)i releasewhenexpressed inHEK-293 cells. (Ca
2)imobilization
was determined fromHEK-293 cells transiently transfectedwith CLR and RAMP1 (n 5) (A), RAMP2 (n 5) (B), and RAMP3 (n 5) (C). Cells were stimulated for
2 min with CGRP, AM, and AM2. Data are expressed as percentage of the maximal (Ca2)i release as determined using 10 M ionomycin. To determine the
contribution made by different G proteins to the (Ca2)i response, cells were preincubated with either PTX (to inhibit Gi) or YM-254890 (a selective Gq
inhibitor). All values are means S.E. of n individual data sets.
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is at least a measure of agreement between the HEK-293 and
yeast data, suggesting that the latter may be a guide as to what
could be seen in mammalian cells given the appropriate condi-
tions. Comparing the relative bias plots for yeast and HEK-293
cells in Figs. 7 and 9 further emphasizes this correlation; the
pattern shown for the two systems is broadly similar. As the
effects of RAMPs on GPCR pharmacology are known to be
sensitive to the cell line background (37, 42) and significant
heterogeneity in PTX sensitivity of CGRP has been reported
previously (20, 45), it would perhaps be surprising if the HEK-
293 cells were a perfect match to yeast. Indeed, as we have
shown (Fig. 6), in terms of the expression levels of Gi subunits,
two similar HEK-293 cell lines are, in fact, very different; HEK-
239S cells appear to have a reduced level of Gi expression
compared with HEK-293 cells. When combined with our
observation of the PTX sensitivity of the CLR response inHEK-
293S cell lines, it becomes apparent that we need to carefully
consider the G protein content of cell lines that we utilize when
investigating G protein-mediated signaling bias.
Our results have demonstrated that the CGRP family of
receptors can couple to Gs, Gi and Gq subunits. Further,
using the yeast system we observed a ligand-dependent G pro-
tein coupling bias with each receptor, highlighting the ability of
the yeast platform to uncover potential G protein bias for other
GPCRs. Importantly, this ability is, at least partially, transferred
into mammalian cells and provides an excellent starting point
for subsequent investigations into both the extent to which this
bias occurs in native mammalian cells and the molecular basis
for the phenomenon. Any examination of the physiological sig-
nificance of G protein promiscuity needs to consider the cellu-
lar background in which the CLR/RAMP receptor is expressed;
we observed significant differences between our three cell hosts
that depend, at least partly, on the G proteins they express (Fig.
13). Indeed, it is worth highlighting that, as a direct conse-
quence of the reduced overall Gi content in HEK-293S cells,
all three ligands at the CGRP family of receptors display bias
toward cAMP accumulation over (Ca2)i release (Fig. 9). Cou-
pling to Gi (or possibly Go) may be particularly relevant in
neuronal and other electrically excitable cells where many (18,
19) of the effects of PTX on CGRP have been observed
(reviewed in Ref. 15). In neuronal and other cells, the direct
Gi/Go effects on ion channelsmay also be particularly signif-
icant. For example, there is the potential for a complex interplay
between neuronally released CGRP and the AM or AM2 pep-
tides released locally through cross-talk among all three CLR-
based receptors, with the potential for the Gi coupling to nat-
urally limit excitation produced via Gs.
The role ofGq/11 coupling inmediating responses toCGRP,
AM, and AM2 has not been well investigated; the few relevant
studies have examined activation of protein kinase C or release
of calcium from internal stores rather than directly studying
Gq/11. For CGRP, a further complication is that it can also
activate the amylin-1 receptor with high affinity (46), so it is not
always clear that the observed effects are mediated via CLR.
However, in HEK-293 cells, alveolar epithelial cells, dorsal root
ganglia, and trigeminal ganglia, there is evidence for either
release of intracellular calcium or activation of PKC alongside
PKA activation (15). A similar pattern has been seen for AM in
bovine aortic endothelial cells (47). Although evidence from
PKA inhibitors such as H89 suggests that cAMP is the primary
second messenger that mediates many effects of CGRP (48),
there is the potential for spatial and temporal modulation of
this primary signal via (Ca2)i, a possibility that remains to be
explored.
By utilizing molecular models of two diverse class B GPCR
systems, namely the RAMP1-CLR-CGRP and RAMP2-GCGR-
glucagon systems, we have gained insight into signaling bias.
Webelieve the simulations reported here are the firstmolecular
dynamics simulations on RAMP-GPCR heterodimers. The
interaction of the RAMP TM helix with TM6/TM7 is sup-
ported both by docking experiments onCLR (27) and by studies
on the secretin-GLP-1 chimeric receptor (49); this interaction
remains stable throughout both 500-ns simulations of the
active receptors, with the RAMP retaining a straight helix
through both simulations, despite the presence of proline(s).
The interaction is primarily with TM7 and the N-terminal end
of TM6. This provides some evidence that GCGR andCLRmay
interact with RAMP in a similar way. Despite the persistence
TABLE 5
Potency (pEC50), affinity (pKa), and coupling efficacy (log ) values for (Ca
2)imobilization at the CLR co-expressed with each RAMP stimulated
with various agonists measured in HEK-293 and HEK-293S cells
Data are themean S.E. of n individual data sets. Statistical significance compared with the cognate ligand (*, p 0.05; **, p 0.01; ***, p 0.001; ****, p 0.0001) for each
receptor heterodimer (CGRP for RAMP1-CLR and AM for CLR with either RAMP2 or RAMP3) was determined by one-way ANOVA with Dunnett’s post-test.
HEK-293 HEK-293S
pEC50a Emaxb pKac log d n pEC50a Emaxb pKac log d n
RAMP1
CGRP 8.19 0.1 79.68 0.7 7.50 0.1 0.60 0.05 5 8.06 0.1 67.64 2.0 7.57 0.1 0.32 0.04 5
AM 7.90 0.2 37.00 3.5**** 7.69 0.4 0.24 0.10 5 7.63 0.2 38.18 3.8**** 7.42 0.2 0.21 0.07**** 5
AM2 6.76 0.2*** 25.05 2.4**** 6.64 0.1** 0.48 0.06** 5 6.94 0.1*** 33.28 1.7**** 6.76 0.1** 0.30 0.03**** 5
RAMP2
CGRP 7.86 0.1 63.20 3.0 7.43 0.1 0.54 0.10 5 7.55 0.3 55.35 4.5 7.21 0.3 0.07 0.08 5
AM 7.86 0.1 63.00 1.8 7.45 0.2 0.19 0.06 5 7.68 0.2 52.26 4.5 7.39 0.2 0.03 0.10 5
AM2 7.41 0.4 44.41 7.1* 7.15 0.4 0.10 0.13** 5 7.42 0.4 20.17 2.8**** 7.33 0.2 0.65 0.13*** 5
RAMP3
CGRP 7.47 0.2* 84.39 8.5* 6.66 0.4* 0.74 0.26 5 7.51 0.2 65.3 4.7 7.07 0.2** 0.24 0.10* 5
AM 8.12 0.1 56.69 6.6 7.76 0.3 0.13 0.13 5 8.02 0.2 44.3 3.2 8.56 0.2 0.11 0.06 5
AM2 8.05 0.3 19.99 2.4* 7.95 0.3* 0.63 0.08* 5 7.44 0.3 20.1 4.3 7.35 0.3** 0.62 0.07** 5
a The negative logarithm of the agonist concentration required to produce a half-maximal response.
b The maximal response to the ligand expressed as a percentage of the maximal (Ca2)i release as determined using 10 M ionomycin stimulation.
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34).
d Log  is the coupling efficacy parameter of each ligand.
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and stability of the TM interactions, the C terminus is quite
flexible, sampling a wide region of space in both simulations.
RAMP2 interacted primarily with the C terminus of Gs,
whereas RAMP1 interacted primarily with H8 but also made
contact with TM6 and most importantly Gs. These simula-
tions therefore indicate that the RAMP could affect the bias
shown inGprotein coupling byCLR either by direct interaction
and/or allosterically by altering the orientation of TM6 and
TM7 or H8. These simulations were carried out on a model of
the active receptor in complex with a C-terminal fragment of
Gs (Arg-374 to Leu-394). The C-terminal helix of Gs sits
above the face of the G protein. Models of RAMP2-GCGR in
complex with the G protein heterotrimer indicated that the
RAMP could also interact directly with residues around Gly-
353 of Gs (results not shown).
In addition, the allosteric effects of the RAMP linker may
alter the extracellular face of the receptor (as seen in CLR with
RAMP2 and RAMP3 (27)), and these effects could be transmit-
ted to the intracellular end of the helix. In our simulations, we
see some evidence for the top of TM7moving in toward theTM
bundle under pressure of the RAMP (Fig. 11) as part of a col-
lective unit comprising TM7, the peptide, and the RAMP TM.
This concerted movement provides a possible mechanism
whereby the influence of the ligand can be conveyed to the
RAMP and thereby affect the bias via interactions of the C ter-
minus of the RAMP. The inwardmovement of the extracellular
FIGURE 9. Quantification of biased agonism at the three RAMP-CLR complexes. A, normalized transduction coefficients, log (/Ka), for cAMP
accumulation and (Ca2)imobilization obtained for the three RAMP-CLR complexes upon stimulated with CGRP, AM, or AM2 in untreated HEK-293 cells,
HEK-293 cells treated with PTX, and HEK-293S cells. B, relative bias factors, (/Ka), for cAMP accumulation and (Ca
2)i mobilization for the three
individual RAMP-CLR complexes upon stimulatedwith CGRP, AM, or AM2 in untreated HEK-293 cells, HEK-293 cells treatedwith PTX, and HEK-293S cells.
Determination of values requires normalization to a reference ligand (CGRP for RAMP1-CLR and AM for CLR with RAMP2 or RAMP3) and a reference
pathway (in all cases cAMP accumulation). Data were determined as statistically different from the cognate ligand for each receptor (*, p 0.05; **, p
0.01; ***, p  0.001; ****, p  0.0001).
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end of TM7 has been linked explicitly to activation (50), but
movement of TM6 and/orH8 under the influence of the RAMP
may also affect bias and activation. Thus we suggest that
RAMPs have the potential to interact allosterically with not
only the GPCR but also the bound G protein. This leads to the
possibility that, upon ligand binding, the RAMPs contribute to
the G protein bias. To confirm this likelihood, we aim to extend
this project to investigate all ligand-RAMP-CLR-G protein
complexes and further elucidate the role that RAMPs play in
modulating G protein coupling and bias at the CGRP family of
receptors.
Finally, we suggest that this study has broader implications.
Our results shown here are similar to those described for the
GCGR (25) in that RAMPs alter the ability of peptides to stim-
ulate different G proteins. However, as we have shown, signifi-
cant pharmacological differences can be observed in differing
recombinant cell lines and expression systems. These differ-
ences can be explained through several factors; these systems
rely firstly upon overexpression of the receptor and chaperone
proteins under study and secondly upon the cellular content of
further downstream signaling proteins such as G proteins. It is
therefore important that findings in systems such as those
FIGURE 10. Class B GPCR-RAMP heterodimericmodels andmolecular dynamics simulations.Molecular models and dynamic simulation suggest that the
C-terminal tail of RAMP1/2 (olive/yellow, when in complex with either GCGR (A, blue) or CLR (B, teal), interacts directly with the bound C-terminal of Gs (green)
and/orhelix 8. Theglucagonpeptideagonist is shown inmagenta, andCGRP is shown inpurple.C, theRAMP2C terminus approaches theGs (redarrow) during
amolecular dynamics simulation of an active GCGR-RAMP2-glucagon complex. RAMP2 is shown in yellow andGs in green, and theGCGR is colored according
to time progression from red (0 ns) to blue (500 ns).
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explained here be further validated. This would be best
achieved in cell lines endogenously expressing the GPCR and
RAMPof interest. This is thus something that we aim to under-
take as a follow-up to the work presented here for CLR-RAMP
complexes. It is clear that there is a complex interplay among
the ligand, the RAMP, and the CLR that alters G protein acti-
vation for these receptors. Further, our data presented here add
to the growingwealth of literature suggesting thatmany ligands
for class B GPCRs display either a Gs or Gi signaling prefer-
ence. To date, this ligand-engendered bias has been observed
for receptors binding corticotropin-releasing factor, urocortin
1, GLP-1, and glucagon (24, 25, 51). In the current study, the
yeast growth assay system was able to provide a valuable indi-
cation of the potential of the CGRP family of receptors to cou-
ple to either Gs or Gi when stimulated by CGRP, AM, or
AM2, allowing us to uncover novel G protein signaling prefer-
ences for each ligand.We therefore conclude that this system is
a good platform from which to explore the effect of RAMP
dimerization to other members of the class B GPCRs.
Experimental Procedures
Materials—Human (h) CGRP, hAM, and hAM2 (1–47)
were purchased from Bachem (Bubendorf, Switzerland) and
made to 1 mM stocks in water containing 1% BSA. Yeast nitro-
gen base and yeast extract were purchased fromDifco (Franklin
Lakes, NJ). Fluorescein-di--D-glucopyranoside was purchased
from Invitrogen. Forskolin was from Tocris Bioscience (Wilt-
shire, UK), andYM-254890was supplied byAlpha Laboratories
(Hampshire, UK). Both theALPHAScreen andLANCE cAMP
detection assay kits and all reagentswere fromPerkinElmer Life
Sciences.
Expression Constructs—To enable expression of the human
CLR, we used either a previously described (25) Myc-tagged
cDNA construct provided by Dr. Michel Bouvier (University of
Montreal, Canada) or a human CLR with an N-terminal HA
epitope tag. All human FLAG-tagged RAMPs were used as
described previously (37).
Yeast Strain Construction and Assay—General yeast proce-
dures were performed as described previously (22, 24). The
humanCLRwas introduced into yeast cells under the control of
the PGK promoter using a plasmid containing ura3 (pDT-
PGK). The three human RAMPs were introduced into yeast
under the control of theGAPDH promoter using plasmids con-
FIGURE 11. The peptide agonist, the GPCR , and the RAMP TM helix move as a collective unit during molecular dynamics simulations. A, schematic
diagram of the distances between themembers of the collective unit and TM2. Top, arrow bars indicate the following distances in order: RAMP2-TM2 (green),
TM7-TM2 (cyan), and peptide-TM2 (orange). Bottom, arrow bars indicate the distances within the members of the collective unit in order: RAMP2-peptide
(purple), RAMP-TM7 (black), and TM7-peptide (red). B, distances from each of the collective unit components (RAMP TM, TM7, and glucagon agonist) to TM2
(ordered as in A). These distances decrease in a similar manner, reflecting their concerted movement. C, distances between each of the collective unit
components (RAMP, TM7, and glucagon agonist) (ordered as in A). These distances are relatively constant, reflecting their movement as a collective unit.
FIGURE 12. Agonist potency ratios for CGRP, AM, and AM2 at the CLR in
combinationwitheachRAMP.Logpotency ratios (asmeasuredby theaccu-
mulation of intracellular cAMP) are defined as log(EC50 AM2/EC50 agonist).
Data are taken fromHong et al. (1) and others (43, 44). HEK-293 andHEK-293S
cell data from the current study are shown in red and blue, respectively, and
yeast Gs coupling is shown in green.
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taining leu2 (p425-GPD) (25). S. cerevisiae dual reporter strains
expressing chimeras of yeast GPA1(1–467) (GPA1/G) with
the five C-terminal amino acids of 11 human G proteins repre-
senting Gs, G16, Gq, Go, Gi1/2, Gi3, Gz, G12, G13, and
G14 (MMY84–MMY93) were used in this study (52). The
human CLR and RAMPs were transformed into yeast cells (at a
ratio of 1:1 to enable equal expression) using the lithium ace-
tate/single-stranded DNA/polyethylene glycol method as
described previously (53). Positive transformants were selected
and maintained on synthetic dropout (SD) medium lacking
both uracil and leucine (SD-Ura-Leu). Receptor signaling was
measured using the yeast growth assay as described previously
(24). Cell growth was initially performed in SD-Ura-Leu
medium at 30 °C to select cells expressing only both plasmids.
Cells were then cultured to remove basal activity in SD-Ura-
Leu-His medium overnight at 30 °C and assayed using medium
supplemented with fluorescein-di--D-glucopyranoside. A flu-
orescein signal was detected as an increase in fluorescence
(excitation wavelength 485 nm, emission wavelength 535
nm) as a measure of growth. Different concentrations of ligand
(0.01 nM–100 M) were assayed using 96-well plates, and fluo-
rescence was detected using a Tecan Infinite M200 microplate
reader (Tecan Ultra Evolution, Reading, UK) or a Mithras LB
940 microplate reader (Berthold Technologies, Harpenden,
UK) for 20 h. Positive isolates were selected for their ability to
grow above basal level in SD-Ura-Leu-Hismedium, when stim-
ulated with 10 M CGRP or AM as appropriate for the RAMP-
CLR complex being studied. Chimeric strains were deemed not
to functionally couple when n  16 isolates had been assayed
and none showed growth above basal levels. In this study func-
tional couplings were only observed for MMY84, MMY86, and
MMY88 representing Gs, Gi1/2, and Gq, respectively.
FIGURE 13. Aworkingmodel of biased agonism at the different RAMP-CLR complexes. The individual RAMP-CLR complexes can bind the agonists CGRP
(red), AM (green), and AM2 (blue) to activate different downstream chimeric GPA1/G subunits (in yeast) or promote increases in intracellular cAMP and/or
mobilize release of (Ca2)i (in HEK-293/HEK-293S cells). The thickness of the lines indicates the bias that each agonist displays for either the chimeric G protein
or the specific downstream signaling cascade. The yeast system enabled the comparison of different individual G proteins (Gs, Gi1/2, and Gq), whereas in
mammalian cells we investigated cAMP accumulation ( PTX) and elevation of (Ca2)i.
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Mammalian Cell Culture and Transfection—HEK-293 cells,
provided by Dr. Jügen Müller (University of Aston), were cul-
tured in DMEM supplemented with 10% heat-inactivated FBS
and kept at 37 °C in a humidified 95% air, 5% CO2 incubator.
HEK-293S cells (a gift from AstraZeneca) were cultured in
DMEM supplemented with 8% heat-inactivated FBS and kept
at 37 °C in a humidified 95% air, 5% CO2 incubator. HEK-293
cells were transfected with FuGENE 6 (Roche Applied Science)
in accordance with the manufacturer’s instructions using a 1:3
(w:v) DNA:FuGENE ratio and a 1:1 ratio of RAMP to CLR.
HEK-293S cells were seeded into 96-well poly-D-lysine-coated
plates at a density of 15,000 cells/well (determined using a
CountessTM cell counter, Invitrogen) 1 day prior to transfec-
tion. HEK-293S cells were transiently transfected as described
previously (38) using a 1:1 ratio of RAMP to CLR. The trans-
fected cell lines were grown for 24–48 h prior to assaying.
Where appropriate, PTX (200 ng/ml) was added to ADP-ribo-
sylate Gi for 16 h prior to assaying, thereby uncoupling recep-
tor-mediated Gi-dependent inhibition of cAMP production.
cAMPAccumulationAssays—The transfectedHEK-293 cells
were washed in PBS, resuspended in stimulation buffer (PBS
containing 0.1% BSA and 0.5 mM IBMX), and seeded at 2000
cells/well in 384-well white Optiplates. Ligands were added in
the range of 1 pM to 1 mM, and cAMP accumulation was mea-
sured after 30min of stimulation using a LANCE cAMPdetec-
tion kit (PerkinElmer Life Sciences). We had found previously
that a 30-min stimulation was the optimum time for assaying
cAMP accumulation for family B GPCRs (24, 25). Plates were
read using a Mithras LB 940 multimode microplate reader
(Berthold Technologies). HEK-293S cells were assayed for
cAMP accumulation as described elsewhere (54). Values were
converted to concentration using a cAMP standard curve per-
formed in parallel.
Calcium Mobilization Assays—Transfected HEK-293 cells
were grown to confluence in black, clear bottomed, 96-well
plates. On the day of assay cells were washed with calcium-free
Hanks’ balanced salt solution and incubated for 1 h at room
temperature in the presence of 10 M Fluo-4/AM (Invitrogen)
containing 2.5 mM probenecid. Cells were then washed fol-
lowed by the addition of 100 l of Ca2-free Hanks’ balanced
salt solution. Ligandswere added robotically using aMithras LB
940multimodemicroplate reader in the range of 10 pM to 1M,
and fluorescence was determined immediately post-injection
with an excitation wavelength set to 485 nm and an emission
wavelength set to 535 nm. Recordings were obtained every 0.5 s
for 120 s. Peak magnitude was calculated using five-point
smoothing followed by correction against background fluores-
cence. The peak was used to generate concentration-response
curves and normalized relative to 10 M ionomycin. To deter-
mine the role played by Gq/11 in (Ca2)i mobilization, cells
were pretreated (for 30 min) with 100 nM YM-254890, which
inhibits Gq/11 signaling (42).
RT-PCR—RNAwas extracted fromHEK-293 and HEK-293S
cells using a RNAqueous-4PCR kit (ThermoFisher Scientific)
as per the manufacturer’s protocol. All RNA samples were
treated with DNase I to remove contaminating genomic DNA.
Reverse transcription was performed using a QuantiTect
reverse transcription kit (Qiagen, Manchester, UK). The PCR
amplification was performed as described previously (55) using
gene-specific primers to humanG subunits: Gs, forward (5	-
CGACGACACTCCCGTCAAC-3	) and reverse (5	-CCCGG-
AGAGGGTACTTTTCCT-3	) (PrimerBank ID, 3297877a1
(56)); Gi1, forward (5	-TTAGGGCTATGGGGAGGTTGA-
3	) and reverse (5	-GGTACTCTCGGGATCTGTTGAAA-3	)
(PrimerBank ID, 156071490c1 (56)); Gi2, forward (5	-TACC-
GGGCGGTTGTCTACA-3	) and reverse (5	-GGGTCGGCA-
AAGTCGATCTG-3	) (PrimerBank ID, 261878574c1 (56));
Gi3, forward (5	-ATCGACCGCAACTTACGGG-3	) and
reverse (5	-AGTCAATCTTTAGCCGTCCCA-3	) (Primer-
Bank ID, 169646784c1 (56)); Gq, forward (5	-TGGGTCAG-
GATACTCTGATGAAG-3	) and reverse (5	-TGTGCATGA-
GCCTTATTGTGC-3	) (PrimerBank ID, 312176363c1 (56));
G11, forward (5	-GGCTTCACCAAGCTCGTCTAC-3	) and
reverse (5	-CACTGACGTACTGATGCTCG-3	) (PrimerBank
ID, 115511048c1) (56)); Gz, forward (5	-GGTCCCGGAGAA-
TTGACCG-3	) and reverse (5	-ATGAGGGGCTTGTACTC-
CTTG-3	) (PrimerBank ID, 45580725c1) (56)); G0, forward
(5	-GGAGCAAGGCGATTGAGAAAA-3	) and reverse
(5	-GGCTTGTACTGTTTCACGTCT-3	) (PrimerBank ID,
162461737c1 (56)); G12, forward (5	-CCGCGAGTTCGACC-
AGAAG-3	) and reverse (5	-TGATGCCAGAATCCCTCCA-
GA-3	) (PrimerBank ID, 42476110c1) (56)); G13, forward
(5	-CAGCAACGCAAGTCCAAGGA-3	) and reverse(5	-
CCAGCACCCTCATACCTTTGA-3	) (PrimerBank ID,
215820623c1) (56)); G14, forward (5	-GAGCGATGGACAC-
GCTAAGG-3	) and reverse (5	-TCCTGTCGTAACACTCC-
TGGA-3	) (PrimerBank ID, 222418795c1 (56)); G15, forward
(5	-CCAGGACCCCTATAAAGTGACC-3	) and reverse
(5	-GCTGAATCGAGCAGGTGGAAT-3	) (PrimerBank ID,
156104882c1 (56)); and GAPDH, forward (5	-AATGGGCAG-
CCGTTAGGAAA-3	) and reverse (5	-GCGCCCAATACGA-
CCAAATC-3	). All products were resolved on a 2% agarose gel
and imaged using a G:Box iChemi gel documentation system
utilizing GeneTools analysis software (Syngene, Cambridge,
UK), and densitometry was performed using GeneTools.
Molecular Modeling—Models of the GCGR in complex with
RAMP2 and CLR in complex with RAMP1 were based on the
previously reported models of GLP-1R in complex with GLP-1
and CLR in complex with RAMP2/3, respectively (27–29).
These models were built using MODELLER 9.16 (57) from the
GCGR and CRFR x-ray structures of the TM domain (58, 59),
the x-ray structures of the extracellular domain (60, 61), and
NMR structures of closely related peptides (62, 63). The helical
region of the CGRP peptide was structurally aligned to the cor-
responding region in GLP-1 based on the sequence alignment
(27) because the position of the GLP1 helix within GLP-1R is
well defined by experimentation; the initialmodels are available
as supporting information. The RAMP-GPCR complexes were
placed in a hydrated POPC membrane using CHARMM GUI
(64) to generate a system containing 20,482 and 28,013 TIP3P
water molecules (65), as well as 183 and 243 lipid molecules for
the RAMP2-GCGR and RAMP1-CLR heterodimers, respec-
tively. The histidine protonation was determined using the
PDB2PQR server (66). TheAMBERSP99 force field parameters
for the protein (67), and the lipid14 force field parameters for
POPC (68, 69) were added using AmberTools (70). Molecular
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dynamics simulations were run for 500 ns at 298 K using
ACEMD (71).
Data Analysis—Data analysis for cAMP assays was per-
formed in GraphPad Prism 6.0f (San Diego, CA). Data were
fitted to obtain concentration-response curves using either the
three-parameter logistic equation (for pEC50 values) or the
operational model for partial agonism (34) to obtain values of
efficacy (log ) and the equilibrium dissociation constant (log
Ka). These values were then used to quantify signaling bias as
change in log (/Ka) relative to the natural cognate ligand for
the respective receptor (41). We denoted these as CGRP for
CLR with RAMP1 and AM for CLR with either RAMP2 or
RAMP3. Statistical differences were analyzed using one-way
ANOVA or Student’s t test as appropriate with post hoc Bon-
ferroni’s or Dunnett’s multiple comparisons, and p 0.05 was
considered significant. Correlations between pEC50 values for
cAMP assays of HEK-293 andHEK-293S cells were assessed by
scatter plot and Pearson’s correlation coefficient (r). For RT-
PCR, normalization to the internal standard GAPDH was per-
formed to reduce variance and enable a comparison between
different cell lines. To quantitate the ligand-dependent
response in the yeast system, a strain lacking GPA1 (MMY11),
grown in rich medium, was used as a standard (72). As GPA1 is
not present in this strain, theG subunits are unregulated and
free to signal, allowing us to determine themaximal response of
our system. Emax values are reported as a percentage of this
maximum response, and statistical analysis was performed on
these data. For the mammalian cell-based assays, data analysis
was carried out as for the yeast curves. To account for the day-
to-day variation experienced from transient transfections, we
used the maximal level of cAMP accumulation from cells in
response to 100 M forskolin stimulation as our reference and
10 M ionomycin for (Ca2)i assays. Emax values from these
curves are reported as a percentage of these controls, and all
statistical analysis has been performed on these data. Where
appropriate the operational model for partial agonism (34) was
used to obtain efficacy (log ) and equilibrium disassociation
constant (log Ka) values. In both cases, this normalization
removes the variation due to differences in transfection or
transformation but retains the variance for control values. The
means of individual experiments were combined to generate
the curves shown.
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